BCC marks the second non-melanoma skin cancer for which Libtayo has demonstrated first-in-class data, the firms note

Sanofi and Regeneron’s have lifted the lid on new topline data on their PD-1 inhibitor Libtayo (cemiplimab) in patients with advanced basal cell carcinoma (BCC), the most common skin cancer in the world, with around two million new cases diagnosed each year in the US alone.

Drug has shown “clinically meaningful responses” for basal cell carcinoma

Two antibody cocktails for COVID-19 could be available as early as this autumn

Investors in Regeneron could afford a rare smile in these difficult times, as the company’s first quarter…

• Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group

Sanofi and Regeneron’s Dupixent has become a popular treatment for atopic dermatitis and asthma. Now, a research team in Japan has discovered that IL-4 and its receptor—which Dupixent inhibits—could be promising targets for treating the eye disease age-related macular degeneration.

New study explores whether dampening IL-6 could address serious coronavirus infections